Chengdu Easton Biopharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688513.SS

Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2023: USD 0.00

Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Chengdu Easton Biopharmaceuticals Co., Ltd. Goodwill for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Shanghai Stock Exchange: 688513.SS

Chengdu Easton Biopharmaceuticals Co., Ltd.

CEO	Mr. Mingxu Yuan
IPO Date	Sept. 2, 2020
Location	China
Headquarters	No.8, Xiyuan Avenue
Employees	1,400
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.

Key trends

Past 5 years